Is One Statin Pill a Week Enough?
Is One Statin Pill a Week Enough?
Abstract & commentary
By Harold L. Karpman, MD, FACC, FACP, Clinical Professor of Medicine, UCLA School of Medicine. Dr. Karpman reports no financial relationship to this field of study.
Synopsis: Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes.
Source: Ruisinger JF, et al. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009;103:393-394.
Published data have demonstrated that instead of administering rosuvastatin on a daily basis, alternative dosing schedules (every other day, three times a week, and twice a week) for patients with previous adverse events, presumably secondary to statin therapy, have improved patient tolerability and at the same time are capable of significantly lowering total serum cholesterol and low-density lipoprotein cholesterol (LDL-C).1-3 These results were probably possible because of rosuvastatin's long half-life (approximately 19 hours)4 and, because the LDL-C reduction was significant5 in these studies, it has been suggested that rosuvastatin might be an attractive statin agent for a weekly dosing schedule.
Ruisinger and her colleagues mounted a study in an attempt to test the efficacy of once-a-week rosuvastatin on the lipid profile in patients with previous adverse events presumably secondary to a statin drug. The once-a-week schedule was tolerated by 74% of the patients with doses ranging from 2.5 to 20 mg once weekly. Nearly all patients (92%) were also taking other lipid-altering agents such as ezetimide, nicotinic acid, fibrates, bile acid sequestrants, and/or omega-3 fatty acids. Patients tolerating the once-a-week dosing regimen experienced a 17% reduction in total cholesterol, a 23% reduction in LDL-C, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all significant, P < 0.001) during a mean follow-up period of 4 months.
Commentary
It is important to recognize that the retrospective observational study reported by Ruisinger was performed in a very small group of patients (n = 50) and was not placebo-controlled. The lipid-lowering effects of once-a-week rosuvastatin proved to be statistically significant; however, no attempt was made to determine whether this alternative dosing regimen was capable of reducing cardiovascular events over the course of this relatively short-term study. Patients with lipid levels measured 1-3 days and 4-7 days after receiving their last rosuvastatin dose had similar mean LDL-C reductions. The are several explanations as to why rosuvastatin was so well tolerated in the study including: Lower plasma concentrations from infrequent drug dosing are less likely to cause adverse effects, simply switching to a different statin quite possibly could have helped some patients tolerate the medication, and/or the psychological effects of taking the medication only once a week may have contributed to the improved drug tolerance in this small group of patients who otherwise might have experienced an adverse effect if treated with a daily statin drug.
Obviously, long-term studies are needed to assess the tolerability and efficacy of once-a-week rosuvastatin administration and to determine whether this regimen is capable of reducing cardiovascular events as has been demonstrated in many of the reported daily-dosage statin trials. The once-a-week dosing schedule was well tolerated in this small group of patients with a history of adverse events to 1 or more statin drugs and led to significantly improved lipoprotein levels, but large randomized trials are needed to confirm these findings and determine whether the once-a-week alternative dosing schedule is more desirable than no statin therapy at all for statin-intolerant patients with abnormally elevated serum lipids.
References
1. Backes JM, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42:341-346.
2. Mackie BD, et al. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol 2007;99:291.
3. Gadarla M, et al. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747-1748.
4. Lopez LM. Rosuvastatin: A high potency HMG-CoA reductase inhibitor. J Am Pharm Assoc 2005;45: 503-513.
5. Jones PH, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-160.
Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.